



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

15 March 2023
EMA/HMPC/135921/2023
Human Medicines Division

Committee on Herbal Medicinal Products (HMPC)

Minutes for the meeting on 13-15 March 2023

Chair: Emiel Van Galen, Vice-Chair: Karin Erika Svedlund

Disclaimers

Some of the information contained in this set of minutes is considered commercially confidential or sensitive and therefore not disclosed.

Of note, this set of minutes is a working document primarily designed for HMPC members and the work the Committee undertakes.

Note on access to documents

Some documents mentioned in the set of minutes cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to ongoing procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the [Agency policy on access to documents](#) (EMA/729522/2016).

Official address Domenico Scarlattilaan 6 • 1083 HS Amsterdam • The Netherlands

Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us

Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000

An agency of the European Union



Table of contents

1.	Introduction	5
1.1.	Welcome and declarations of interest of members, alternates and experts.....	5
1.2.	Adoption of agenda.....	5
1.3.	Adoption of the minutes	5
2.	EU herbal monographs and list entries for adoption	5
2.1.	Status of HMPC activities.....	5
2.1.1.	Overview of HMPC assessment work including the Rapporteurship distribution – Status in March 2023.....	5
2.1.2.	Appointment of Rapporteurs and Peer-reviewers	6
2.1.3.	Maydis stigma – new proposal for assessment.....	6
2.1.4.	Pruni cerasi stipites – for information	7
2.2.	Revised EU herbal monographs and list entries for final adoption	7
2.2.1.	Monograph on Juniperi pseudo-fructus (galbulus) and supporting documents.....	7
2.3.	Revised EU herbal monographs and list entries for public consultation	7
2.4.	Reviewed EU herbal monographs and list entries for decision on revision.....	7
2.4.1.	Monograph on Crataegi folium cum flore and supporting documents	7
2.4.2.	Monograph on Helichrysi flos and supporting documents	8
2.5.	EU herbal monographs, list entries and public statements for adoption for release for public consultation.....	8
2.5.1.	Monograph on Cisti cretici herba and supporting documents	8
2.6.	EU herbal monographs, list entries and public statements - post finalisation.....	8
3.	Referral procedures	8
4.	Guidelines and guidance documents	9
4.1.	Non-clinical/clinical safety and efficacy and multidisciplinary.....	9
4.1.1.	Public statement on use of herbal medicinal products containing estragole (EMA/HMPC/137212/2005 Rev 1)	9
4.1.2.	Guideline on the assessment of genotoxicity of herbal substances/preparations (EMA/HMPC/107079/2007)	9
4.2.	Quality.....	9
4.2.1.	Guideline on good agricultural and collection practice (GACP) of starting materials of herbal origin (EMA/HMPC/246816/2005)	9
4.3.	Regulatory / Procedural	10
4.4.	Report on HMPC Drafting Groups activities.....	10
4.4.1.	Herbal Quality DG – Member re-appointment	10
4.4.2.	Herbal Quality DG – Chair election.....	10
4.4.3.	ORGAM DG	10
4.4.4.	Ad-hoc Quality drafting group	10

5.	Organisational, regulatory and methodological matters	11
5.1.	Mandate and organisation of the HMPC	11
5.1.1.	Strategic Review and Learning Meetings (SRLM)	11
5.1.2.	HMPC membership	11
5.1.3.	Election of HMPC Vice-Chair	11
5.1.4.	Document collaborative platform – Teams integration	12
5.2.	EMA Scientific Committees or CMDh-v	12
5.2.1.	Scientific Coordination Board Meeting	12
5.3.	Coordination with EMA Working Parties/Working Groups/Drafting Groups	12
5.4.	Cooperation within the EU regulatory network	12
5.4.1.	Coordination with European Pharmacopoeia	12
5.4.2.	Coordination with the European Commission	13
5.5.	Cooperation with International Regulators	13
5.6.	Contacts of the HMPC with external parties and interaction with the Interested Parties to the Committee	13
5.7.	Work plan and related activities	13
5.7.1.	HMPC work plan 2023	13
5.8.	Planning and reporting	15
5.8.1.	HMPC meeting organisation 2023	15
5.8.2.	HMPC meeting dates 2025-2026	15
5.9.	Legislation and regulatory affairs	15
5.9.1.	Request on Article 16c Directive 2001/83/EC	15
5.10.	Questions from members	16
6.	EU herbal monographs and list entries in preparation	16
6.1.	Revision of EU herbal monographs and list entries in preparation for adoption after public consultation	16
6.1.1.	Monograph on Foeniculi amari fructus and supporting documents - postponed	16
6.1.2.	Monograph on Foeniculi amari fructus aetheroleum and supporting documents - postponed	16
6.1.3.	Monograph on Foeniculi dulcis fructus and supporting documents - postponed	16
6.1.4.	Monograph on Fumariae herba and supporting documents	16
6.2.	Revision of EU herbal monographs and list entries in preparation for public consultation	16
6.2.1.	Monograph on Eucalypti aetheroleum and supporting documents - postponed	16
6.2.2.	Monograph on Lavandulae aetheroleum and supporting documents	16
6.2.3.	Monograph on Ginseng radix and supporting documents	17
6.2.4.	Monograph on Pelargonii radix and supporting documents	17
6.2.5.	Monograph on Plantaginis lanceolatae folium and supporting documents	17
6.2.6.	Monograph on Rhodiolae roseae rhizoma et radix and supporting documents	18
6.2.7.	Monograph on Urticae herba and supporting documents - postponed	18

6.2.8.	Monograph on Urticae radix and supporting documents - postponed	18
6.2.9.	Monograph on Zingiberis rhizoma and supporting documents.....	18
6.3.	Review of EU herbal monographs and list entries in preparation for decision on revision	19
6.3.1.	Monograph on Capsici fructus and supporting documents	19
6.3.2.	Monograph on Ginkgo folium and supporting documents	19
6.3.3.	Monograph on Matricariae flos and supporting documents	20
6.3.4.	Monograph on Melaleucae aetheroleum and supporting documents.....	20
6.3.5.	Monograph on Myrtilli fructus siccus and supporting documents.....	21
6.3.6.	Monograph on Myrtilli fructus recens and supporting documents.....	21
6.3.7.	Monograph on Ononidis radix and supporting documents.....	21
6.3.8.	Monograph on Origani majoranae herba and supporting documents.....	22
6.3.9.	Monograph on Pileosellae herba cum radice and supporting documents.....	22
6.3.10.	Monograph on Polygoni avicularis herba and supporting documents	23
6.3.11.	Monograph on Pruni africanae cortex and supporting documents - postponed	23
6.3.12.	Monograph on Ricini oleum and supporting documents.....	23
6.3.13.	Monograph on Rosae flos and supporting documents - postponed.....	23
6.3.14.	Monograph on Rubi idaei folium and supporting documents	23
6.3.15.	Monograph Sideritis herba and supporting documents - postponed	24
6.3.16.	Monograph on Sisymbrii officinalis herba and supporting documents.....	24
6.3.17.	Monograph on Symphyti radix and supporting documents - postponed.....	24
6.4.	EU herbal monographs and list entries in preparation for adoption after public consultation.....	24
6.5.	EU herbal monographs and list entries in preparation for adoption for release for public consultation	25
6.5.1.	Monograph on Hyperici herba/Cimicifugae rhizoma and supporting documents.....	25
6.5.2.	Monograph on Tribuli terrestris herba and supporting documents - postponed.....	25
7.	Any other business	25
7.1.	Topics for discussion	25
7.1.1.	Availability of ESCOP monographs for HMPC assessment work	25
7.1.2.	Monograph on Matricariae aetheroleum and supporting documents.....	25
7.2.	Documents for information.....	26
7.2.1.	HMPC.....	26
7.2.2.	Assessment Report Summary for the Public (ARSP)	26
7.2.3.	Other	26
	List of participants	27

1. Introduction

1.1. Welcome and declarations of interest of members, alternates and experts

The Chair opened the meeting by welcoming all participants. The meeting was held in-person with some members connected remotely.

In accordance with the Agency's policy on handling of declarations of interests of scientific Committees' members and experts, based on the declarations of interest submitted by the Committee members, alternates and experts and based on the topics in the agenda of the meeting, the Committee Secretariat announced that no restriction in the involvement of meeting participants for agenda topics was identified (see list of participants).

Participants were asked to declare any changes, omissions or errors to their declared interests concerning the matters for discussion. No new or additional competing interests were declared.

Discussions, deliberations and voting took place in full respect of the restricted involvement of Committee members and experts in line with the relevant provisions of the [Rules of Procedure](#). All decisions taken at this meeting were made in the presence of a quorum of members. All decisions, recommendations and advice were agreed by consensus, unless otherwise specified.

The Chair welcomed the new member(s) and alternate(s) and thanked the departing members/alternates for their contributions to the Committee.

1.2. Adoption of agenda

HMPC agenda for 13-15 March 2023.

Outcome:

Agenda and time schedule adopted with postponement of the monograph on *Cisti cretici herba*.

1.3. Adoption of the minutes

HMPC minutes for 23-25 January 2023.

Outcome:

Minutes adopted with changes introduced prior to the start of meeting.

2. EU herbal monographs and list entries for adoption

2.1. Status of HMPC activities

2.1.1. Overview of HMPC assessment work including the Rapporteurship distribution – Status in March 2023

Report: HMPC Chair

Action: For discussion

Document tabled: Overview

Outcome:

HMPC noted the status of assessment work.

In case of postponement of topics scheduled for the HMPC January 2023 meeting according to the overview, Rapporteurs were asked to inform secretariat and Chair before the first pre-mail (by 25 April 2023) to allow best adaptation of agenda and time-schedule.

2.1.2. Appointment of Rapporteurs and Peer-reviewers

Systematic Reviews

- Symphyti radix
- Thymi herba
- Matricariae aetheroleum

Outcome:

HMPC agreed on Rapporteurs and Peer reviewers for the above systematic reviews (see also 7.1.2).

New assessments started in 2023

- Pruni cerasi stipites
- Species pectoralis
- Cannabis flos

Outcome:

HMPC agreed on Rapporteurs and Peer reviewers for the above new assessments to start in 2023.

For *Prunus cerasus* a Rapporteur will be appointed at the HMPC May meeting.

2.1.3. Maydis stigma – new proposal for assessment

Action: For discussion

Documents: Validated proposal for assessment, references

Outcome:

Proposal for assessment to be modified according to the discussion and possible additional information from HMPC members such as on marketed products in EU MSs other than Poland.

Modified proposal and new information to be provided to the secretariat for validation by 28 April before next **discussion** with **possible adoption** scheduled at the **HMPC May 2023** meeting.

Members discussed the tradition in and outside Europe as well as quality standards and correct terminology. Some MSs (EL, ES) signalled that additional information on marketed products in medicinal use (including posology) may be possible to be provided to the Rapporteur.

2.1.4. Pruni cerasi stipites – for information

Action: For information

Documents: Amended proposal for assessment, new references

Outcome:

The HMPC welcomed the additional information and references provided, including the SmPC of a product from French market to ensure the availability of essential data (e.g. concerning posology).

While a call for data has already been published, a Rapporteur has yet to be appointed (see 2.1.2) and then also the correct Latin name of the substance to be confirmed.

2.2. Revised EU herbal monographs and list entries for final adoption

2.2.1. Monograph on Juniperi pseudo-fructus (galbulus) and supporting documents

Action: For adoption

Documents tabled: MO, AR, LoR, Reader's Guidance, presentation

Outcome:

Final revised EU herbal monograph and supporting documents adopted by majority (27 out of 28). Divergent opinion: Netherlands. The Norwegian delegate expressed a favourable position.

Rapporteur highlighted the main changes introduced in the revised MO, with updating the name of herbal substance (*Juniperus communis* L. galbulus (pseudo-fructus)) and the information in section 5.3. Preclinical safety data ("No adequate tests on reproductive toxicity and no tests on genotoxicity and carcinogenicity have been performed"). HMPC agreed to modify in the AR the summary of the Eudravigilance report adding information on adverse events that were taken into account without mentioning the type of events when not reliable. The HMPC also agreed to maintain the posology for the comminuted cone berries and the liquid extract (DER 1:1) with ethanol 25% v/v, although the peer reviewer had pointed to some differences in consideration of daily dosages from traditional sources that could have some safety relevance.

2.3. Revised EU herbal monographs and list entries for public consultation

None

2.4. Reviewed EU herbal monographs and list entries for decision on revision

2.4.1. Monograph on Crataegi folium cum flore and supporting documents

Action: For adoption

Document tabled: Review report

Outcome:

HMPC agreed with Rapporteur's position to revise the EU herbal monograph because new data were detected that require update and changes to the content of the monograph. The HMPC decided by consensus to start the revision procedure and revise the monograph, assessment report and list of references on *Crataegi folium cum flore*. The review report was adopted and HMPC tracking documents will be updated.

The Rapporteur pointed out that there are new clinical safety data (e.g. change of adverse effects frequency) and also new information on the use of the comminuted herbal substance is available. Furthermore the updated Ph. Eur. monograph excluding now a specific *Crataegus* species as source plant was mentioned.

2.4.2. Monograph on *Helichrysi flos* and supporting documents

Action: For adoption

Document tabled: Review report

Outcome:

HMPC agreed with Rapporteur's position that no EU herbal monograph revision is needed because no new data of relevance were detected that would change the content of the monograph.

The HMPC decided by consensus not to revise the monograph, assessment report and list of references on *Helichrysi flos*.

The review report was adopted and after editorial review will be published as addendum to the existing assessment report on the EMA website.

The Rapporteur emphasised that there is no new scientific data/information, no new herbal substances/preparations with 30/15 years of TU or 10 years of WEU that may justify a revision of the MO.

2.5. EU herbal monographs, list entries and public statements for adoption for release for public consultation

2.5.1. Monograph on *Cisti cretici herba* and supporting documents

Action: For adoption

Documents tabled: none

Outcome:

Postponed.

2.6. EU herbal monographs, list entries and public statements - post finalisation

None

3. Referral procedures

None

4. Guidelines and guidance documents

4.1. Non-clinical/clinical safety and efficacy and multidisciplinary

4.1.1. Public statement on use of herbal medicinal products containing estragole (EMA/HMPC/137212/2005 Rev 1)

Action: For discussion

Document tabled: Public statement – draft correction

Outcome:

Small group to discuss and finetune with secretariat and Rapporteurs the proposed footnote for correcting the public statement vis-à-vis other options as regards Table 1.

Next **discussion** with **possible adoption** scheduled at the **HMPC May 2023** meeting.

Members discussed possible misunderstandings from the content of Table 1 in national and MRP/DCP procedures. The relevance of plants in food vis-à-vis medicines as well as the strength of data on the estragole content in various plant parts were debated.

4.1.2. Guideline on the assessment of genotoxicity of herbal substances/preparations (EMA/HMPC/107079/2007)

Action: For discussion

Document tabled: [Concept paper](#), comments received

Outcome:

HMPC noted comments received during the public consultation on the concept paper.

Rapporteur to prepare a first draft of the revised guideline or a list of potential issues to be addressed by HMPC members.

Next **discussion** scheduled at the **HMPC May 2023** meeting.

4.2. Quality

4.2.1. Guideline on good agricultural and collection practice (GACP) of starting materials of herbal origin (EMA/HMPC/246816/2005)

Action: For information

Documents tabled: Presentation

Outcome:

Draft revised GACP guideline to be modified according to the discussion and after further development sent to the transitional herbal QDG for further comments and review before presentation to the Committee.

Next **discussion** scheduled at the **HMPC May 2023** meeting.

After a presentation on key points by a Co-Rapporteur, HMPC discussed some issues known to cause difficulties in procedures and ideally to be addressed during the revision for more clarity: the status of powdered herbal substances, requirements on the collection from the wild, the specific consideration of indoor cultivation, common drying techniques, fumigation with CO₂ as well as relevance of the GL for herbal starting materials of 'non-herbal' MPs.

Furthermore the later involvement of Inspectors was advocated and reference made to GMP Q&A (EMA/INS/GMP/48514/2021) in this respect.

4.3. Regulatory / Procedural

None

4.4. Report on HMPC Drafting Groups activities

4.4.1. Herbal Quality DG – Member re-appointment

Report: HMPC Chair, Nicoleta Carmen Purdel

Action: For adoption

Documents tabled: [Mandate QDG](#), Call, Presentation, Re-nominations

Outcome:

The HMPC endorsed nine (9) quality experts still active as members of the transitional herbal Quality DG for the continuation of drafting activities until implementation of the new quality domain structure (Anna Maria Serilli, Burt H Kroes, Carmen Purdel, Friederike Stolte, Knut Almgren, Kristine Hvolby, Olga Palomino, Reinhard Länger, Sari Koski).

4.4.2. Herbal Quality DG – Chair election

Report: HMPC Chair, Nicoleta Carmen Purdel

Action: For adoption

Documents tabled: [Mandate QDG](#), Call, Presentation, Candidatures

Outcome:

The HMPC confirmed by majority according to current mandate Carmen Purdel as Chairperson of the transitional herbal Quality DG leading the drafting activities but also serving as link to the Quality domain implementation group and old/new QWP to support the HMPC Chair until the new domain groups are implemented.

4.4.3. ORGAM DG

None

4.4.4. Ad-hoc Quality drafting group

Report: Nicoleta Carmen Purdel

Action: For information

Document tabled: Minutes February 2023

Outcome:

The HMPC members noted the ongoing activities of Quality DG mainly related to the concept paper on the development of a reflection paper on newly used manufacturing techniques regarding herbal medicinal preparation, the update/revision of Q&As on the quality of herbal medicinal products (EMA/HMPC/41500/2010), and the Q&A from QWP on how to use a CEP

in the context of a MAA (marketing authorisation application) or a MAV (marketing authorisation variation).

5. Organisational, regulatory and methodological matters

5.1. Mandate and organisation of the HMPC

5.1.1. Strategic Review and Learning Meetings (SRLM)

- HMPC SRLM Follow up plan - status March 2023

Report: HMPC Vice Chair

Action: For information

Document tabled: Follow up plan

Outcome:

The HMPC members heard a brief update of the SRLM follow up plan.

- Swedish Presidency meeting – 18-19 April 2023

Report: Karin Erika Svedlund

Action: For discussion

Document tabled: Draft Agenda, presentation

Outcome:

The HMPC members took note of the draft agenda for the virtual meeting of the HMPC SRLM organised by the Swedish Presidency of the Council of the European Union and to be held on 18-19 April 2023 (invitations have already been sent to HMPC members).

5.1.2. HMPC membership

Report: HMPC Chair

Action: For information

Outcome:

There were no changes to inform in regard to HMPC membership.

5.1.3. Election of HMPC Vice-Chair

Action: For adoption

Documents tabled: Call for expression of interest, [HMPC RoP](#), Candidature, presentation

Outcome:

The election of HMPC Vice-Chair took place in line with the HMPC Rules of Procedure. Karin Erika Svedlund from the Lakemedelsverket (The Swedish Medical Products Agency) was re-elected as HMPC Vice-Chair for a second 3-year mandate starting 05 May 2023.

Karin Erika Svedlund emphasised that the HMPC's main priority for the next 3 years should remain the establishment/ revision of EU herbal monographs (and that all members of the Committee are involved in this process); however, as Vice-Chair she also pays particular

attention to strategic developments as reflected in work plan projects. Strategic objectives of the HMPC should include improvements in the harmonisation of the safe use of herbal medicinal products in children and for example the role of mono-monographs for combination products applications or the potential role of HMPC monographs in borderline discussions. Coordination with other groups within and outside EMA should be increased.

5.1.4. Document collaborative platform – Teams integration

Action: For discussion

Document tabled: Presentation

Outcome:

HMPC was briefed on 'Teams' (a Microsoft tool) as a collaborative platform for sharing/editing documents and holding meetings online. The HMPC members were invited to access 'HMPC' in 'Teams' and report any related issues.

Specific 'channels' (topics) relevant to HMPC work are about to be created in 'Teams' and the HMPC secretariat will inform members involved in each topic.

5.2. EMA Scientific Committees or CMDh-v

5.2.1. Scientific Coordination Board Meeting

Report: HMPC Chair

Action: For information

Document tabled: Draft agenda

Outcome:

The HMPC Chair summarised the relevant topics on the agenda of the Scientific Coordination Board (SciCoBo) meeting held on 3 March focusing on the closure of the EMA BCP, new experts management tool and the foreseen EU pharmaceutical review.

5.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups

None

5.4. Cooperation within the EU regulatory network

5.4.1. Coordination with European Pharmacopoeia

- EDQM 13A expert group meeting
Report: Melanie Bald, Bruno Spieldenner
Action: For information
Document tabled: SoD
- EDQM 13B expert group meeting
Report: Melanie Bald, Bruno Spieldenner
Action: For information

Document tabled: SoD

- EDQM TCM expert group meeting

Report: Melanie Bald, Bruno Spieldenner

Action: For information

Document tabled: SoD

Outcome:

The HMPC noted the summaries of decisions from the March 2023 13A group meeting (next meeting in June 2023), the January 2023 13B group meeting (next meeting in April 2023) and the January 2023 TCM group meeting (next meeting in April 2023) and other ongoing work with regard to Ph. Eur. herbal quality standards presented by the EDQM observer.

The possible input of EDQM on herbal substance Latin names, even without current Ph. Eur. available, was briefly discussed and proposed to double check substance names recently added to the HMPC work programme once all Rapporteurs have been appointed and details are better known with start of the assessment.

5.4.2. Coordination with the European Commission

None

5.5. **Cooperation with International Regulators**

None

5.6. **Contacts of the HMPC with external parties and interaction with the Interested Parties to the Committee**

None

5.7. **Work plan and related activities**

5.7.1. HMPC work plan 2023

Report: HMPC Chair

Action: For discussion

Documents tabled: Work plan 2023, Annex 1, Annex 2 – current status

Outcome:

The HMPC members noted current status of projects, monographs and guidelines.

- (1.3.1) Evaluation of data from paediatric clinical practice for the safe use of herbal substances in children

Action: For discussion

Documents tabled: Presentation

Outcome:

The Rapporteur summarised briefly main issues reviewed so far on the draft discussion paper on data requirements for the use of HMPs in children/adolescents (e.g. whether formulation aspects should be part of the quality or clinical requirements, what aspects of

the PDCO extrapolation guidance could be applied to HMPs, and whether data from food supplements could be supportive for TU (for the WEU this was not considered acceptable)). Next, it is planned to continue with the clinical part, therapeutic areas and possible age cut-offs for paediatric indications without medical supervision. A draft for comments is intended to be presented at the HMPC May meeting.

- (1.3.2) Harmonise the approach for the use of EU herbal monographs in the assessment of combination products

Action: For information

Documents tabled: Meeting Summary

Outcome:

The Rapporteur pointed out that a revision of the current Guideline in the Clinical assessment of fixed combinations of herbal substances/herbal preparations (EMA/HMPC/166326/2005) was deemed unnecessary. Instead, it was considered to check the general herbal efficacy guideline to address specifics for herbal fixed combinations. An updated review of existing guidelines and other reference documents related to herbal combinations (to obtain a clear "state of the art" and use it as a starting point) was also suggested.

- (2.2.1) Prepare a new Communication Initiative for HMPC stakeholders on herbal products

Action: For information

Documents tabled: Presentation, Survey

Outcome:

The Rapporteur highlighted some activities planned for 2023, such as comparing existing national initiatives through a survey in order to identify needs and experiences and then analysing the information collected towards a viable proposal for a better presentation of HMPC assessments.

The HMPC discussed the value, analysis, purpose and confidentiality of the information requested and members were invited to provide feedback to the Rapporteurs on the draft survey.

A presentation given at the last PCWP regarding Herbal MPs and the planned initiative was distributed and short feedback provided.

- (2.2.2) Training on assessment of applications for herbal medicinal products

Outcome:

The Rapporteur underlined the collaboration with EDQM in preparing, hosting and recording the next training for herbal medicinal products (via EU NTC herbal curriculum) to be held on 27 April 2023.

Action: For discussion

- (2.3.1) Implement new working methodology for HMPC – new main procedure and revised template documents

Action: For discussion

Documents tabled: Draft Procedure establishment monographs, Draft revised AR template, Draft revised AR template with comments, Reader's guidance

Outcome:

The HMPC noted the additional changes to be included in the draft revised AR template for further discussion at the HMPC May 2023 meeting.

The HMPC members were invited to send their written comments to the Rapporteurs. Rapporteurs to update and complete the new combined draft procedure for establishment of monographs for possible endorsement at the HMPC May 2023 meeting.

It was acknowledged that the procedure could be progressed and finalised as much as possible, while the revised AR template, that will form an Annex to the procedure, may take more time for agreement.

5.8. Planning and reporting

5.8.1. HMPC meeting organisation 2023

Report: HMPC Chair

Action: For information

Document tabled: Email communication

Outcome:

The HMPC Chair summarised the arrangements for the remaining HMPC meetings in 2023: May and September to be held as face-to-face meetings; July and November to be held as virtual meetings.

In May, the meeting will start on Wednesday the 10th at 9 AM and in this regard HMPC members were informed to preferably arrive on Tuesday the 9th.

5.8.2. HMPC meeting dates 2025-2026

Report: HMPC Chair

Action: For information

Document tabled: Draft meeting schedule

Outcome:

The HMPC noted the arrangements for HMPC meetings in 2025 and 2026. No objections were raised.

A document with only the HMPC meeting dates will be prepared and published on the EMA/HMPC dedicated webpage.

5.9. Legislation and regulatory affairs

5.9.1. Request on Article 16c Directive 2001/83/EC

Action: For discussion

Document tabled: Presentation

Outcome:

The HMPC noted the EMA proposal to recommend to the European Commission a correction of Article 16c(1)(a)(iii) of Directive 2001/83/EC in the context of the ongoing revision of

pharmaceutical legislation. After EC response a reply will be given to the requesting Interested Party.

The HMPC members also confirmed that the error is known at NCA level as well as by pharmaceutical companies.

5.10. Questions from members

None

6. EU herbal monographs and list entries in preparation

6.1. Revision of EU herbal monographs and list entries in preparation for adoption after public consultation

6.1.1. Monograph on *Foeniculi amari fructus* and supporting documents - postponed

6.1.2. Monograph on *Foeniculi amari fructus aetheroleum* and supporting documents - postponed

6.1.3. Monograph on *Foeniculi dulcis fructus* and supporting documents - postponed

6.1.4. Monograph on *Fumariae herba* and supporting documents

Action: For 1st discussion

Documents tabled: Draft MO, AR, LoR, Reader's Guidance

Outcome:

No comments were received during public consultation. Rapporteur to finalise the draft revised EU herbal monograph and supporting documents for peer review and **adoption** at the **HMPC May 2023** meeting.

Timetable:

Documents to be sent to Peer-reviewer: **07 April 2023**

Peer-review documents to be sent to Rapporteur: **21 April 2023**

Final documents to be included latest in 2nd premail: **02 May 2023**

6.2. Revision of EU herbal monographs and list entries in preparation for public consultation

6.2.1. Monograph on *Eucalypti aetheroleum* and supporting documents - postponed

6.2.2. Monograph on *Lavandulae aetheroleum* and supporting documents

Action: For 9th discussion

Documents tabled: Draft MO, AR, LoR, Reader's Guidance, Presentation

Outcome:

Rapporteur to introduce changes in the draft revised EU herbal monograph and supporting documents according to the discussion and possible further comments from peer-reviewer

and HMPC members.

Next **discussion** scheduled at the **HMPC May 2023** meeting.

6.2.3. Monograph on Ginseng radix and supporting documents

Action: For 2nd discussion

Documents tabled: Draft MO, AR, LoR, Reader's Guidance

Outcome:

Rapporteur to introduce changes in the draft revised EU herbal monograph and supporting documents according to the discussion and possible further comments from peer-reviewer and HMPC members, for **possible adoption** for public consultation at the **HMPC May 2023** meeting.

Timetable:

Documents to be sent to Peer-reviewer: **07 April 2023**

Peer-review documents to be sent to Rapporteur: **21 April 2023**

Final documents to be included latest in 2nd premail: **02 May 2023**

The Rapporteur summarised the main changes introduced in the AR (chapter 3.4. Overall conclusions on non-clinical data and chapter 4. Clinical data have both been shortened).

HMPC members discussed the particularly wide range and amount of clinical studies with heterogeneous results and advantages/ disadvantages of assessing single specific endpoints versus overall clinical evidence associated with the adaptogenic concept.

6.2.4. Monograph on Pelargonii radix and supporting documents

Action: For 6th discussion

Documents tabled: Draft MO, AR, LoR, Reader's Guidance

Outcome:

Rapporteur to introduce changes in the draft revised EU herbal monograph and supporting documents according to the discussion and possible further comments from peer-reviewer and HMPC members.

Next **discussion** scheduled at the **HMPC May 2023** meeting.

The Rapporteur highlighted 3 issues for clarification in MO sections 2, 4.1 and 4.2. The HMPC discussed mainly the use in children in terms of availability of (usage) data, comparability of preparations, specific concerns with regard to the ethanol content (as part of the extract/ active substance or the finished product) and analogies to other comparable substances and uses. The Rapporteur proposals will be re-discussed at the HMPC May meeting.

6.2.5. Monograph on Plantaginis lanceolatae folium and supporting documents

Action: For 3rd discussion

Documents tabled: Draft MO, AR, LoR, Reader's Guidance

Outcome:

Rapporteur to introduce changes in the draft revised EU herbal monograph and supporting documents according to the discussion and possible further comments from peer-reviewer and HMPC members, for **possible adoption** for public consultation at the **HMPC May 2023** meeting.

Timetable:

Documents to be sent to Peer-reviewer: **07 April 2023**

Peer-review documents to be sent to Rapporteur: **21 April 2023**

Final documents to be included latest in 2nd premail: **02 May 2023**

The HMPC noted the Rapporteur's proposal to consider both oral use and oromucosal use for preparation b (lozenge; registered for "Traditionally used for the strengthening of the respiratory tract") in the MO indication "Traditional herbal medicinal product as a demulcent for the symptomatic treatment of oral or pharyngeal irritations and associated dry cough". The HMPC also agreed with the Rapporteur's proposal to consider one (1) week as the duration of use in skin conditions.

Furthermore, missing information on two new Polish preparations was clarified.

6.2.6. Monograph on *Rhodiolae roseae rhizoma et radix* and supporting documents

Action: For 2nd discussion

Documents tabled: Draft MO, AR, LoR, Reader's Guidance

Outcome:

Rapporteur to introduce changes in the draft revised EU herbal monograph and supporting documents according to the discussion and possible further comments from peer-reviewer and HMPC members.

Next **discussion** scheduled at the **HMPC May 2023** meeting.

The Rapporteur highlighted the alignment with the Peer-reviewer on the previously proposed MO amendments related to indication, interactions and adverse events. Rapporteur to rephrase the wording used to describe the findings of the clinical interaction study (Thu et al. 2016b) as mentioned in the AR section 5.5.4 and then conclude on the warning to be included in MO section 4.5 Interactions.

6.2.7. Monograph on *Urticae herba* and supporting documents - postponed

6.2.8. Monograph on *Urticae radix* and supporting documents - postponed

6.2.9. Monograph on *Zingiberis rhizoma* and supporting documents

Action: For 5th discussion

Documents tabled: Draft MO, AR, LoR, Reader's Guidance

Outcome:

Rapporteur to introduce changes in the draft revised EU herbal monograph and supporting documents according to the discussion and possible further comments from peer-reviewer and HMPC members, for **possible adoption** for public consultation at the **HMPC May 2023** meeting.

Timetable:

Documents to be sent to Peer-reviewer: **07 April 2023**

Peer-review documents to be sent to Rapporteur: **21 April 2023**

Final documents to be included latest in 2nd premail: **02 May 2023**

The Rapporteur underlined the previous proposal to keep the duration of use for travel sickness only as "single use before travel" (MO section 4.2). Members took further note of the unchanged conclusions regarding use during pregnancy and lactation (original proposal by IPs for unscheduled review) and the reasons (data and Eudravigilance check) for not having an explicit warning on bleeding.

6.3. Review of EU herbal monographs and list entries in preparation for decision on revision

6.3.1. Monograph on Capsici fructus and supporting documents

Action: For 1st discussion

Document tabled: Review report

Outcome:

Rapporteur to prepare a first draft of the review report according to the discussion.

Next **discussion** scheduled at the **HMPC May 2023** meeting.

The Rapporteur summarised the results of the literature search and raised 3 points for discussion. (1) The use of the WHO Vigibase was considered in terms of value of quantitative and qualitative information and the mandatory or optional check for substances e.g. less frequent in EU MPs and thus 'underreported' in the Eudravigilance database.

(2) HMPC agreed to include in the MO review report publicly available data supporting the WEU indication of 'diabetic polyneuropathy'. Evidence on different types of pain and options for treatment according to etiology and mechanisms involved may still need more discussion. Some HMPC members stressed also that adverse events "application site pain" and "burning sensation, stinging" may have different physiological mechanisms behind. (3) Furthermore, HMPC noted the Rapporteur's position not to consider herbal preparations related to some products that were identified in the market overview of the previous AR for the revised monograph WEU part. Possibilities for TU were not yet checked.

6.3.2. Monograph on Ginkgo folium and supporting documents

Action: For 3rd discussion

Document tabled: Review report

Outcome:

HMPC endorsed the Rapporteur's position that there is relevant new information available that could change the content of the EU herbal monograph and therefore a revision of the complete package is advocated.

Rapporteur to finalise the review report and send for peer review before **adoption** at the **HMPC May 2023** meeting.

Timetable:

Documents to be sent to Peer-reviewer: **07 April 2023**

Peer-review documents to be sent to Rapporteur: **21 April 2023**
Final documents to be included latest in 2nd premail: **02 May 2023**

The Rapporteur stressed that a MO revision is deemed necessary to include the new clinical safety data (additional cardiac adverse effects). Also amendments in the wording of other sections of the monograph are required, e.g. 4.5..

Furthermore, the Rapporteur confirmed that data is available in the public domain to support the assessment. HMPC briefly discussed need for coordination with PRAC once the monograph has been revised. Several reasons were given that no PRAC procedure is currently to be expected and no risk of possible overlap in activities exists.

6.3.3. Monograph on *Matricariae flos* and supporting documents

Action: For 1st discussion

Document tabled: Review report

Outcome:

HMPC endorsed the Rapporteur's position that there is relevant new information available that could change the content of the EU herbal monograph and therefore a revision of the complete package is advocated.

Rapporteur to finalise the review report and send for peer review before **adoption** at the **HMPC May 2023** meeting.

Timetable:

Documents to be sent to Peer-reviewer: **07 April 2023**

Peer-review documents to be sent to Rapporteur: **21 April 2023**

Final documents to be included latest in 2nd premail: **02 May 2023**

The Rapporteur pointed out that reasons for MO revisions have been identified, for instance for preparation b) a recognised TU in additional indications and dosages is available and therefore a change of the MO is recommended.

6.3.4. Monograph on *Melaleuca aetheroleum* and supporting documents

Action: For 2nd discussion

Document tabled: Review report

Outcome:

HMPC endorsed the Rapporteur's position that there is no new information available that could change the content of the EU herbal monograph.

Rapporteur to finalise the review report and send for peer review before **adoption** at the **HMPC May 2023** meeting.

Timetable:

Documents to be sent to Peer-reviewer: **07 April 2023**

Peer-review documents to be sent to Rapporteur: **21 April 2023**

Final documents to be included latest in 2nd premail: **02 May 2023**

The Rapporteur summarised that there are no new products on the EU market, nor are there any new indications, herbal preparations and dosage forms other than those already

in the MO. Moreover, adverse events retrieved from the pharmacovigilance database and published case reports are already included in the current MO.

6.3.5. Monograph on *Myrtilli fructus siccus* and supporting documents

Action: For 1st discussion

Document tabled: Review report

Outcome:

HMPC endorsed the Rapporteur's position that there is no new information available that could change the content of the EU herbal monograph.

Rapporteur to finalise the review report and send for peer review before **adoption** at the **HMPC May 2023** meeting.

Timetable:

Documents to be sent to Peer-reviewer: **07 April 2023**

Peer-review documents to be sent to Rapporteur: **21 April 2023**

Final documents to be included latest in 2nd premail: **02 May 2023**

The Rapporteur pointed out that the reference to the Ph. Eur. updated monographs could be considered later when there is a fundamental need to review the MO.

6.3.6. Monograph on *Myrtilli fructus recens* and supporting documents

Action: For 1st discussion

Document tabled: Review report

Outcome:

HMPC endorsed the Rapporteur's position that there is no new information available that could change the content of the EU herbal monograph.

Rapporteur to finalise the review report and send for peer review before **adoption** at the **HMPC May 2023** meeting.

Timetable:

Documents to be sent to Peer-reviewer: **07 April 2023**

Peer-review documents to be sent to Rapporteur: **21 April 2023**

Final documents to be included latest in 2nd premail: **02 May 2023**

The Rapporteur pointed out that the reference to the Ph. Eur. updated monographs could be considered later when there is a fundamental need to revise the MO. This is in line with previous decisions that a change of reference to the Ph. Eur. quality standard does not represent a change of HMPC conclusions on safety and use of the herbal substances and as such no reason for revision.

6.3.7. Monograph on *Ononidis radix* and supporting documents

Action: For 2nd discussion

Document tabled: Review report, Reader's guidance

Outcome:

Rapporteur to modify the review report according to the discussion and possible additional comments from peer-reviewer and HMPC members.

Next **discussion** scheduled at the **HMPC May 2023** meeting.

The Rapporteur highlighted issues related to the fluid intake restrictions in defined patient groups (with heart insufficiency, kidney injury) using herbal tea of restharrow root preparations, and as a consequence, a revision of MO sections 4.3 and 4.4 is proposed (whether to consider previous discussion on juniper berry MO or discuss individual data on restharrow root MO). Moreover, the indication "Traditional herbal medicinal product used to increase the amount of urine to achieve flushing of the urinary tract as an adjuvant in minor urinary complaints" (MO section 4.1) was suggested to be subject of discussion and eventual improvement in the future.

(See also 6.3.9 - breakout session to be organised)

6.3.8. Monograph on *Origanum majorana* herba and supporting documents

Action: For 2nd discussion

Document tabled: Review report

Outcome:

Rapporteur to modify the review report according to the discussion and possible additional comments from peer-reviewer and HMPC members.

Next **discussion** scheduled at the **HMPC May 2023** meeting.

The Rapporteur highlighted that potential new indications (oral use: 'neuralgia'; cutaneous use: 'neuralgia, rheumatic pain'), herbal preparations (for indications 'gastrointestinal complaints' and 'relief of symptoms in coughs and colds') and dosages (for indication 'irritated skin around nostrils') were identified.

Some HMPC members expressed concerns about the proposed dosages/posology for old unspecified wine tincture preparations, that had not been found acceptable for the first version of the monograph.

6.3.9. Monograph on *Pilosella* herba cum radice and supporting documents

Action: For 1st discussion

Document tabled: Presentation

Outcome:

Rapporteur to prepare a first draft of the review report according to the discussion and comments and suggestions from the breakout session with Rapporteurs in charge of the MOs with the indication "Traditional herbal medicinal product used to increase the amount of urine to achieve flushing of the urinary tract as an adjuvant in minor urinary tract complaints".

Next **discussion** scheduled at the **HMPC May 2023** meeting.

The Rapporteur pointed out that there are no (new) herbal products on the market since 2015 and that no new data were provided during the call for scientific data launched in 2022. Four new publications and two serious adverse events (one with hepatitis; in all reported cases there was concomitant use of other herbs and other medicines (paracetamol)) were identified.

While no new data would justify any revision in this case, the Rapporteur had a class review for consistency with comparable substances: 23 out 30 MOs have recommendation for fluid intake (but not *Pilosellae herba cum radice*).

Following a comparable initiative in 2022 with some agreements already, the HMPC Secretariat was asked to organise a breakout session with all Rapporteurs in charge of the MOs with the indication "Traditional herbal medicinal product used to increase the amount of urine to achieve flushing of the urinary tract (as an adjuvant) in minor urinary tract complaints" to prepare a proposal for harmonisation of those MOs.

6.3.10. Monograph on *Polygoni avicularis herba* and supporting documents

Action: For 2nd discussion

Document tabled: Review report

Outcome:

HMPC agreed to defer *Polygoni avicularis herba* for **discussion** at the **HMPC May 2023** meeting.

(See also 6.3.9 - breakout session to be organised)

6.3.11. Monograph on *Pruni africanae cortex* and supporting documents - postponed

6.3.12. Monograph on *Ricini oleum* and supporting documents

Action: For 1st discussion

Document tabled: Review report

Outcome:

HMPC endorsed the Rapporteur's position that there is no new information available that could change the content of the EU herbal monograph.

Rapporteur to finalise the review report and send for peer review before **adoption** at the **HMPC May 2023** meeting.

Timetable:

Documents to be sent to Peer-reviewer: **07 April 2023**

Peer-review documents to be sent to Rapporteur: **21 April 2023**

Final documents to be included latest in 2nd premail: **02 May 2023**

The Rapporteur highlighted that some clinical trials that investigated the efficacy of castor oil as bowel preparation for colon capsule endoscopy (CCE) were identified. Nevertheless, as there are no products identified on the EU market for more than 10 years with such purgative purpose, the new data will not trigger a revision of MO to include the WEU for that indication. The findings from those clinical trials can be supportive for the clinical safety of castor oil.

6.3.13. Monograph on *Rosae flos* and supporting documents - postponed

6.3.14. Monograph on *Rubi idaei folium* and supporting documents

Action: For 2nd discussion

Documents tabled: Review report, Reader's guidance

Outcome:

HMPC endorsed the Rapporteur's position that there is no new information available that could change the content of the EU herbal monograph.

Rapporteur to finalise the review report and send for peer review before **adoption** at the **HMPC May 2023** meeting.

Timetable:

Documents to be sent to Peer-reviewer: **07 April 2023**

Peer-review documents to be sent to Rapporteur: **21 April 2023**

Final documents to be included latest in 2nd premail: **02 May 2023**

The Rapporteur pointed out that various articles discussing possible non-clinical and clinical effects of raspberry leaf were identified, but none of this new data was considered to change the MO. Furthermore, no new safety issues were detected from the EudraVigilance database.

6.3.15. Monograph *Sideritis herba* and supporting documents - postponed

6.3.16. Monograph on *Sisymbrii officinalis herba* and supporting documents

Action: For 3rd discussion

Documents tabled: Review report, Reader's Guidance

Outcome:

HMPC endorsed the Rapporteur's position that there is no new information available that could change the content of the EU herbal monograph.

Rapporteur to finalise the review report and send for peer review before **adoption** at the **HMPC May 2023** meeting.

Timetable:

Documents to be sent to Peer-reviewer: **07 April 2023**

Peer-review documents to be sent to Rapporteur: **21 April 2023**

Final documents to be included latest in 2nd premail: **02 May 2023**

The Rapporteur pointed out that there is a new product authorised in Belgium, but with the herbal preparation, pharmaceutical form and therapeutic indication already covered by the current MO. Although the posology is stratified based on the age and it is slightly different from that included in the MO, after check of the BE product it resulted that the change of the posology cannot be considered as supported by the TU. This change is rather justified based on the difference in body weight of a 12-year-old-adolescent and a 6-year-old-child.

6.3.17. Monograph on *Symphyti radix* and supporting documents - postponed

6.4. EU herbal monographs and list entries in preparation for adoption after public consultation

None

6.5. EU herbal monographs and list entries in preparation for adoption for release for public consultation

6.5.1. Monograph on *Hyperici herba/Cimicifugae rhizoma* and supporting documents

Action: For 4th discussion

Documents tabled: Draft MO, AR, Reader's Guidance

Outcome:

Rapporteur to introduce changes in the draft EU herbal monograph and supporting documents according to the discussion and possible additional comments from peer-reviewer and HMPC members.

Next **discussion** scheduled at the **HMPC May 2023** meeting.

Rapporteurs and committee members discussed available data and comparability/extrapolation of information on products on the market. For instance, it was noted that there is no 30 years (with 15 years in the EU) of TU for inclusion of herbal preparation b) in MO. Moreover, the HMPC stressed that data behind any information on warnings, interactions, adverse events in the monograph, should be presented in the AR and assessed for possible inclusion in the MO; independent whether some information can be found in product SmPCs.

6.5.2. Monograph on *Tribuli terrestris herba* and supporting documents - postponed

7. Any other business

7.1. Topics for discussion

7.1.1. Availability of ESCOP monographs for HMPC assessment work

Action: For discussion

Document tabled: Email communication

Outcome:

The HMPC noted options to access the latest ESCOP monographs. A case-by-case approach was agreed in which Rapporteur at the start of the MO review also checks the latest ESCOP update available. If no available access e.g. via university/NCA the HMPC secretariat can be contacted to check purchase via the EMA information centre. Thus, the latest version can be made available when required.

7.1.2. Monograph on *Matricariae aetheroleum* and supporting documents

Action: For discussion

Outcome:

Following the data provided upon the Call for data for the revision of the EU herbal monograph on *Matricariae flos* (see 6.3.3) and the proposal of the Rapporteur for revision, the HMPC agreed to also initiate the systematic review procedure of *Matricariae*

aetheroleum and publish a Call for data. Rapporteurs will be the same as for 'flos' (see 2.1.2). The decision to keep a joint AR will be taken at later stage.

7.2. Documents for information

7.2.1. HMPC

Table of Decisions from HMPC meeting held on 23-25 January 2023

Overview of expertise of members HMPC and subgroups

[Inventory of herbal substances for assessment work](#)

[Abbreviations in HMPC agendas/minutes](#)

Common names of herbal substances in all languages

Final Monograph Overview

HMPC plenary Best Practice Guide with annexed Reader's Guidance template

7.2.2. Assessment Report Summary for the Public (ARSP)

On hold

7.2.3. Other

- Agenda - Pharmacovigilance herbal MP conference at Kew Gardens, 13-14 April 2023 (draft presentation E. Svedlund)
- Meeting Summary – PCWP-HCPWP meeting with all eligible organisations - 15 Nov November 2022
- Agenda - PCWP-HCPWP Joint meeting – 3 March 2023
- Paediatric uses of herbal medicines (updated document: Jan 2023)

Outcome:

EMA and HMPC re-confirmed support to the Vice-Chair participation in the Pharmacovigilance herbal MP conference at Kew Gardens. The draft presentation was welcomed. Any comments/corrections should be sent to the Vice Chair.

List of participants

List of participants including any restrictions with respect to involvement of members/alternates/experts following evaluation of declared interests for the 13-15 March 2023 meeting.

Name	Role	Member state or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Astrid Obmann	Alternate	Austria	No interests declared	
Peter Voitl	Co-opted member	Austria	No interests declared	
Reinhard Länger	Member	Austria	No interests declared	
Gert Laekeman	Co-opted member	Belgium	No interests declared	
Patricia Bodart	Member	Belgium	No interests declared	
Iliana Ionkova	Member	Bulgaria	No interests declared	
Radina Dimitrova	Alternate	Bulgaria	No interests declared	
Darko Trumbetic	Alternate	Croatia	No interests declared	
Ivan Kosalec	Member	Croatia	No interests declared	
Alexandra Demetriou	Alternate	Cyprus	No interests declared	
Marie Heroutova	Alternate	Czechia	No interests declared	
Nanna Lundgaard Rasmussen	Alternate	Denmark	No interests declared	
Maria Paile Hyvarinen	Member	Finland	No interests declared	
Sari Koski	Alternate	Finland	No interests declared	
An Le	Member	France	No interests declared	
Heidi Foth	Co-opted member	Germany	No interests declared	
Jacqueline Wiesner	Member	Germany	No interests declared	
Susanne Flemisch	Alternate	Germany	No interests declared	
Ioanna Chinou	Member	Greece	No interests declared	
Stavroula Mamoucha	Alternate	Greece	No interests declared	
Rita Nemeth	Alternate	Hungary	No interests declared	
Jacqueline Masterson	Alternate	Ireland	No interests declared	
Sarah Kellaghan	Member	Ireland	No interests declared	
Alessandro Assisi	Member	Italy	No interests declared	

Name	Role	Member state or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Anna Maria Serrilli	Alternate	Italy	No interests declared	
Inga Sile	Member	Latvia	No interests declared	
Asta Kubiliene	Alternate	Lithuania	No interests declared	
Greta Budukeviciute	Member	Lithuania	No interests declared	
Sven Back	Member	Luxembourg	No interests declared	
Everaldo Attard	Member	Malta	No interests declared	
Matthew Camilleri	Alternate	Malta	No interests declared	
Burt H Kroes	Member	Netherlands	No interests declared	
Emiel Van Galen	Chair	Netherlands	No interests declared	
Hilda Kuin	Alternate	Netherlands	No interests declared	
Gro Anita Fossum	Member	Norway	No interests declared	
Marianne Loiten Dalhus	Alternate	Norway	No interests declared	
Wojciech Dymowski	Member	Poland	No interests declared	
Ana Paula Martins	Member	Portugal	No interests declared	
Eva Mendes	Alternate	Portugal	No interests declared	
Maria da Graca Ribeiro Campos	Co-opted member	Portugal	No interests declared	
Maria Helena Pinto Ferreira	Co-opted member	Portugal	No interests declared	
Carmen Purdel	Member	Romania	No interests declared	
Ligia Elena Dutu	Alternate	Romania	No interests declared	
Miroslava Horváth Petriková	Member	Slovakia	No interests declared	
Jaroslav Tóth	Alternate	Slovakia	No interests declared	
Barbara Razinger	Member	Slovenia	No interests declared	
Olga Maria Palomino	Member	Spain	No interests declared	
Olga Teresa Esteban	Alternate	Spain	No interests declared	
Malin Kyllikki Hobro Soderberg	Alternate	Sweden	No interests declared	
Karin Erika Svedlund	Member (Vice-Chair)	Sweden	No interests declared	
Meeting run with support from relevant EMA staff				

* Experts were evaluated against the agenda topics or activities they participated in.